Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Keryx_Biopharmaceuticals
|
| gptkbp:acquisitionYear |
2018
|
| gptkbp:CEO |
John P. Butler
|
| gptkbp:collaboratedWith |
gptkb:Otsuka_Pharmaceutical
gptkb:Mitsubishi_Tanabe_Pharma |
| gptkbp:focusesOn |
gptkb:anemia
kidney disease |
| gptkbp:foundedIn |
2007
|
| gptkbp:founder |
Joseph Gardner
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Akebia Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
approximately 200 (as of 2023)
|
| gptkbp:product |
gptkb:vadadustat
|
| gptkbp:productType |
pharmaceuticals
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:researchArea |
hypoxia-inducible factor (HIF) pathway
|
| gptkbp:stockSymbol |
AKBA
|
| gptkbp:vadadustatIndication |
anemia due to chronic kidney disease
|
| gptkbp:website |
https://www.akebia.com/
|
| gptkbp:bfsParent |
gptkb:Varenzin-CA1
|
| gptkbp:bfsLayer |
7
|